Branched peptides as bioactive molecules for drug design
Peptide Science · 2018-09 · 110 (5)
DOI: 10.1002/pep2.24089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Peptide Science, online erschienen am 23.09.2018. Verfasst von Jlenia Brunetti und 3 weiteren Autor:innen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Italian Foundation for Cystic Fibrosis.
Abstract (Originalsprache)
Peptides are regarded as good candidates for new biotherapeutics in medicine. Several peptides have already completed clinical development, with more than 60 peptide‐based drugs already on the market, and a further 500 derivatives currently in developmental stages. Branched peptides are an emerging class of synthetic molecules being assessed for drug development. Here, we review possible clinical uses of branched peptides, considering major features such as stability, half‐life, toxicity, and efficacy compared to monomeric peptides, biodistribution, as well as modifications, encapsulation, and conjugation to improve delivery or bypass drug resistance. We focus in particular on the use of branched peptides in oncology and infectious diseases.
Förderung
- Italian Foundation for Cystic Fibrosis
Zitieren
APA
Brunetti, J., Falciani, C., Bracci, L., & Pini, A. (2018). Branched peptides as bioactive molecules for drug design. Peptide Science, 110(5). https://doi.org/10.1002/pep2.24089
Vancouver
Brunetti J, Falciani C, Bracci L, Pini A. Branched peptides as bioactive molecules for drug design. Peptide Science. 2018;110(5). doi:10.1002/pep2.24089
BibTeX
@article{Brunetti2018,
author = {Brunetti, Jlenia and Falciani, Chiara and Bracci, Luisa and Pini, Alessandro},
title = {Branched peptides as bioactive molecules for drug design},
journal = {Peptide Science},
year = {2018},
volume = {110},
number = {5},
doi = {10.1002/pep2.24089}
}
EUVIMED